EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)

Pamela L Kunz iD, Noah T Graham, Paul J Catalano iD, Halla S Nimeiri, George A Fisher iD, Teri A Longacre, Carlos J Suarez iD, Brock A Martin iD, James C Yao iD, Matthew H Kulke iD, Andrew E Hendifar iD, James C Shanks und 7 weitere

Journal of Clinical Oncology · 01.03.2023 · 41 (7) · 1359-1369

DOI: 10.1200/jco.22.01013 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.03.2023. Verfasst von Pamela L Kunz und 18 weiteren Autor:innen. Beteiligte Einrichtung: Yale School of Medicine, New Haven, CT. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Pancreatic Neoplasms. Die Arbeit wurde bisher 231-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Patients with advanced pancreatic neuroendocrine tumors (NETs) have few treatment options that yield objective responses. Retrospective and small prospective studies suggest that capecitabine and temozolomide are associated with high response rates (RRs) and long progression-free survival (PFS). PATIENTS AND METHODS E2211 was a multicenter, randomized, phase II trial comparing temozolomide versus capecitabine/temozolomide in patients with advanced low-grade or intermediate-grade pancreatic NETs. Key eligibility criteria included progression within the preceding 12 months and no prior temozolomide, dimethyl-triazeno-imidazole-carboxamide or dacarbazine, capecitabine or fluorouracil. The primary end point was PFS; secondary endpoints were overall survival, RR, safety, and methylguanine methyltransferase (MGMT) by immunohistochemistry and promoter methylation. RESULTS A total of 144 patients were enrolled between April 2013 and March 2016 to temozolomide (n = 72) or capecitabine and temozolomide (n = 72); the primary analysis population included 133 eligible patients. At the scheduled interim analysis in January 2018, the median PFS was 14.4 months for temozolomide versus 22.7 months for capecitabine/temozolomide (hazard ratio = 0.58), which was sufficient to reject the null hypothesis for the primary end point (stratified log-rank P = .022). In the final analysis (May 2021), the median overall survival was 53.8 months for temozolomide and 58.7 months for capecitabine/temozolomide (hazard ratio = 0.82, P = .42). MGMT deficiency was associated with response. CONCLUSION The combination of capecitabine/temozolomide was associated with a significant improvement in PFS compared with temozolomide alone in patients with advanced pancreatic NETs. The median PFS and RR observed with capecitabine/temozolomide are the highest reported in a randomized study for pancreatic NETs. MGMT deficiency was associated with response, and although routine MGMT testing is not recommended, it can be considered for select patients in need of objective response (ClinicalTrials.gov identifier: NCT01824875 ).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsPancreatic NeoplasmsHumansAntineoplastic Combined Chemotherapy ProtocolsCapecitabineDacarbazineProspective StudiesRetrospective StudiesTemozolomideTreatment Outcome

Substanzen

CapecitabineDacarbazineTemozolomide

Autor:innen und Institutionen

  • Yale School of Medicine, New Haven, CT.
  • Dana-Farber Cancer Institute, Boston, MA.
  • Robert H. Lurie Cancer Center of Northwestern University, Chicago, IL.
  • Stanford University School of Medicine, Stanford, CA.
  • University of Louisville, Louisville, KY.
  • University of Texas MD Anderson Cancer Center, Houston, TX.

ORCID-Profile: Pamela L Kunz, Paul J Catalano, George A Fisher, Carlos J Suarez, Brock A Martin, James C Yao, Matthew H Kulke, Andrew E Hendifar, Manisha H Shah, Diane L Reidy-Lagunes, Jonathan R Strosberg, Al B Benson

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Kunz, P. L., Graham, N. T., Catalano, P. J., Nimeiri, H. S., Fisher, G. A., Longacre, T. A., Suarez, C. J., Martin, B. A., Yao, J. C., Kulke, M. H., Hendifar, A. E., Shanks, J. C., Shah, M. H., Zalupski, M. M., Schmulbach, E. L., Reidy-Lagunes, D. L., Strosberg, J. R., O'Dwyer, P. J., & Benson, A. B. (2023). Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211). Journal of Clinical Oncology, 41(7), 1359-1369. https://doi.org/10.1200/jco.22.01013

Vancouver

Kunz PL, Graham NT, Catalano PJ, Nimeiri HS, Fisher GA, Longacre TA, et al. Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211). Journal of Clinical Oncology. 2023;41(7):1359-1369. doi:10.1200/jco.22.01013

BibTeX
@article{Kunz2023,
  author = {Kunz, Pamela L and Graham, Noah T and Catalano, Paul J and Nimeiri, Halla S and Fisher, George A and Longacre, Teri A and Suarez, Carlos J and Martin, Brock A and Yao, James C and Kulke, Matthew H and Hendifar, Andrew E and Shanks, James C and Shah, Manisha H and Zalupski, Mark M and Schmulbach, Edmond L and Reidy-Lagunes, Diane L and Strosberg, Jonathan R and O'Dwyer, Peter J and Benson, Al B},
  title = {Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {7},
  pages = {1359--1369},
  doi = {10.1200/jco.22.01013}
}
Kostenlos starten →